Trial · NCT07044908
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908, Phase 1, Phase 2, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer. Trials, record NCT07044908. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07044908
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
- NCT number
- NCT07044908
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 72 participants, estimated
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Conditions
- RAS/BRAF Wild Type Colorectal Cancer
- Interventions
- TQB2922 injection ± TAS-102 tablets, TQB2922 injection+TAS-102 tablets ± Bevacizumab
- First posted
- 2025-07-01
- Last updated
- 2025-08-12
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose limiting toxicity (DLT) | Baseline up to 48 weeks | One or more unacceptable toxic reactions following administration of the drug, resulting in the inability to continue increasing the dose or prolonging the dosing cycle. |
| Primary | Objective Response Rate (ORR) | Complete response time was achieved, evaluation is expected to take 1 years. | Proportion of patients with tumour volume reduction to a pre-specified value that maintains the minimum timeframe requirement. |
| Secondary | Maximum tolerated dose (MTD) | Baseline up to 48 weeks | If dose limiting toxicity (DLT) occurs in 2 or more subjects in a given dose group, the dose level in the previous dose group is considered MTD. |
| Secondary | Incidence of adverse event (AE) and serious adverse event (SAE) | Baseline up to 48 weeks | The incidence and severity of adverse events were determined according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 rating scale |
| Secondary | Disease Control Rate (DCR) | Complete response time was achieved, evaluation is expected to take 1 years. | The proportion of subjects who achieved complete response (CR), partial response (PR), or stable disease (SD) was assessed. |
| Secondary | Recommended Phase 2 Dose | Baseline up to 48 weeks | The dose recommended for Phase 2 trials based on Phase 1 safety, tolerability, and pharmacokinetic data. |
| Secondary | Elimination Half-life | Baseline up to 48 weeks | The time required for the plasma concentration of a drug to decrease by 50% during the elimination phase, reflecting metabolic and excretory rates. |
| Secondary | Area Under the Curve | Baseline up to 48 weeks | The integral of the drug concentration-time curve in plasma, representing total systemic drug exposure. |
| Secondary | Apparent Clearance | Baseline up to 48 weeks | The apparent volume of plasma cleared of the drug per unit time, typically expressed in L/h. |
| Secondary | Apparent Volume of Distribution in Terminal Phase | Baseline up to 48 weeks | The apparent volume in which a drug is distributed during the terminal phase, calculated based on plasma concentration, indicating tissue distribution extent. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07044908
GET https://conductscience.org/api/trials/v1/NCT07044908/registered